Literature DB >> 16550716

Markers of bone turnover: biochemical and clinical perspectives.

F Pagani1, C M Francucci, L Moro.   

Abstract

Bone remodelling is a process by which bone grows and turns over. This process involves a series of highly regulated steps that depend on the interaction of two cell lineages, the osteoclasts and the osteoblasts. Information on metabolic activity of bone tissue are achieved with the determination, in blood and in urine, of biochemical products derived from the activity of this cells. The ability to determine bone turnover with biochemical markers has been enhanced considerably in recent years with the development of new assays for more sensitive and specific markers. These new markers can now replace the outdated and non-specific markers of bone remodeling such as serum total alkaline phosphatase (ALP) and urinary hydroxyproline (Hyp) determination. Biochemical markers of bone turnover can be classified according to the process that underlie in markers of bone formation, products of the osteoblast activity [bone ALP, osteocalcin (OC), procollagene I C- and N-terminal propeptides] and markers of bone resorption, products of the osteocalst activity [pyridinuim crosslinks, collagen I C- and N-terminal telopeptides (CTX-I and NTX-I), tartrate resistent acid phosphatase (TRACP) isoform 5b]. The interpretation of laboratory results should always include the consideration of potential sources of variability. Variation in the results of biochemical markers of bone metabolism can compromise their ability to characterize disorders of bone metabolism. Variation can be categorized into pre-analytical, analytical and biological sources. However, the determination of biochemical markers of bone turnover offers many advantages in clinical practice, since they are non-invasive, can be repeated often, and major changes occur in a short time.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16550716

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  35 in total

1.  Quantitative analyses of myelofibrosis by determining hydroxyproline.

Authors:  Wanke Zhao; Wan-Ting Tina Ho; Zhizhuang Joe Zhao
Journal:  Stem Cell Investig       Date:  2015-01-26

2.  Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations.

Authors:  Jihong Li; Yoshiyuki Fukase; Yi Shang; Wei Zou; José M Muñoz-Félix; Lorena Buitrago; Johannes van Agthoven; Yixiao Zhang; Ryoma Hara; Yuta Tanaka; Rei Okamoto; Takeshi Yasui; Takashi Nakahata; Toshihiro Imaeda; Kazuyoshi Aso; Yuchen Zhou; Charles Locuson; Dragana Nesic; Mark Duggan; Junichi Takagi; Roger D Vaughan; Thomas Walz; Kairbaan Hodivala-Dilke; Steven L Teitelbaum; M Amin Arnaout; Marta Filizola; Michael A Foley; Barry S Coller
Journal:  ACS Pharmacol Transl Sci       Date:  2019-08-02

3.  Taxonomy of rare genetic metabolic bone disorders.

Authors:  L Masi; D Agnusdei; J Bilezikian; D Chappard; R Chapurlat; L Cianferotti; J-P Devolgelaer; A El Maghraoui; S Ferrari; M K Javaid; J-M Kaufman; U A Liberman; G Lyritis; P Miller; N Napoli; E Roldan; S Papapoulos; N B Watts; M L Brandi
Journal:  Osteoporos Int       Date:  2015-06-13       Impact factor: 4.507

Review 4.  The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review.

Authors:  L J Peppone; S Hebl; J Q Purnell; M E Reid; R N Rosier; K M Mustian; O G Palesh; A J Huston; M N Ling; G R Morrow
Journal:  Osteoporos Int       Date:  2009-12-04       Impact factor: 4.507

5.  Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents.

Authors:  Nicolau Conte Neto; Luis C Spolidorio; Cleverton R Andrade; Alliny S Bastos; Morgana Guimarães; Elcio Marcantonio
Journal:  Int J Exp Pathol       Date:  2013-02       Impact factor: 1.925

6.  Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure.

Authors:  Ely M Sebastian; Larry J Suva; Peter A Friedman
Journal:  Bone       Date:  2008-08-09       Impact factor: 4.398

7.  Is tartrate-resistant acid phosphatase 5b a potent bio-marker for late stage aseptic implant loosening?

Authors:  Gerrit Steffen Maier; Christian Eberhardt; Marco Strauch; Konstantinos Kafchitsas; Andreas A Kurth
Journal:  Int Orthop       Date:  2014-08-01       Impact factor: 3.075

8.  Single nucleotide polymorphisms in bone turnover-related genes in Koreans: ethnic differences in linkage disequilibrium and haplotype.

Authors:  Kyung-Seon Kim; Ghi-Su Kim; Joo-Yeon Hwang; Hye-Ja Lee; Mi-Hyun Park; Kwang-joong Kim; Jongsun Jung; Hyo-Soung Cha; Hyoung Doo Shin; Jong-Ho Kang; Eui Kyun Park; Tae-Ho Kim; Jung-Min Hong; Jung-Min Koh; Bermseok Oh; Kuchan Kimm; Shin-Yoon Kim; Jong-Young Lee
Journal:  BMC Med Genet       Date:  2007-11-26       Impact factor: 2.103

9.  Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling.

Authors:  Chang Hyun Byon; Amjad Javed; Qun Dai; John C Kappes; Thomas L Clemens; Victor M Darley-Usmar; Jay M McDonald; Yabing Chen
Journal:  J Biol Chem       Date:  2008-03-31       Impact factor: 5.157

10.  Characteristics of bone metabolism markers during the healing of osteoporotic versus nonosteoporotic metaphyseal long bone fractures: a matched pair analysis.

Authors:  L Kolios; M Hitzler; A Moghaddam; C Takur; H Schmidt-Gayk; B Höner; M Lehnhardt; P Grützner; C Wölfl
Journal:  Eur J Trauma Emerg Surg       Date:  2012-04-25       Impact factor: 3.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.